<?xml version='1.0' encoding='utf-8'?>
<document id="29717552"><sentence text="Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients."><entity charOffset="94-103" id="DDI-PubMed.29717552.s1.e0" text="ibuprofen" /></sentence><sentence text="This study was undertaken to determine if a clinically relevant drug-drug interaction occurred between ibuprofen and lumacaftor/ivacaftor"><entity charOffset="103-112" id="DDI-PubMed.29717552.s2.e0" text="ibuprofen" /></sentence><sentence text="" /><sentence text="Peak ibuprofen plasma concentrations were measured prior to and after lumacaftor/ivacaftor initiation"><entity charOffset="5-14" id="DDI-PubMed.29717552.s4.e0" text="ibuprofen" /></sentence><sentence text=" A Wilcoxon signed rank sum test was used to compare the values" /><sentence text="" /><sentence text="Nine patients were included in the final analysis" /><sentence text=" Peak ibuprofen plasma concentrations decreased an average of 36"><entity charOffset="6-15" id="DDI-PubMed.29717552.s8.e0" text="ibuprofen" /></sentence><sentence text="4 mcg/mL after initiation of lumacaftor/ivacaftor with a relative reduction of 41" /><sentence text="7%" /><sentence text=" The average peak plasma concentration was 84" /><sentence text="2 mcg/mL (SD = 10" /><sentence text="9) prior to lumacaftor/ivacaftor initiation and 47" /><sentence text="9 mcg/mL (SD = 16" /><sentence text="4) following initiation (P = 0" /><sentence text="0039)" /><sentence text=" Peak concentrations occurred at an average of 100 min (SD = 30) and 107 min (SD = 40) prior to and following lumacaftor/ivacaftor initiation, respectively" /><sentence text="" /><sentence text="We suggest a clinically relevant drug-drug interaction exists between ibuprofen and lumacaftor/ivacaftor"><entity charOffset="70-79" id="DDI-PubMed.29717552.s19.e0" text="ibuprofen" /></sentence><sentence text=" Lumacaftor may cause subtherapeutic ibuprofen plasma concentrations due to the induction of CYP enzymes and increased metabolism of ibuprofen"><entity charOffset="37-46" id="DDI-PubMed.29717552.s20.e0" text="ibuprofen" /><entity charOffset="133-142" id="DDI-PubMed.29717552.s20.e1" text="ibuprofen" /><pair ddi="false" e1="DDI-PubMed.29717552.s20.e0" e2="DDI-PubMed.29717552.s20.e0" /><pair ddi="false" e1="DDI-PubMed.29717552.s20.e0" e2="DDI-PubMed.29717552.s20.e1" /></sentence><sentence text=" Based on this analysis, we have modified our use of ibuprofen in several patients after evaluation of this drug-drug interaction"><entity charOffset="53-62" id="DDI-PubMed.29717552.s21.e0" text="ibuprofen" /></sentence><sentence text="" /></document>